“Digital Breast Tomosynthesis Market | IndustryARC”

Digital Breast Tomosynthesis Market size is estimated at $2.8 billion in 2021, projected to grow at a CAGR of 13.2% during the forecast period 2022-2027. Digital Breast Tomosynthesis (DBT) is a kind of breast imaging, or mammography, which converts x-ray images of the breast into a three-dimensional image set using low-dose x-ray equipment, electronics, and a computer. It’s used to provide high-resolution limited-angle tomography at radiation doses comparable to protection radiography and for detecting and diagnosing cancer at an early stage. Projectional radiography or conventional radiography produces two-dimensional images by x-ray radiations. DBT is also known as 3d mammography. According to German research published in October 2021 in European Radiology, when compared to conventional mammography alone, combining digital breast tomosynthesis (DBT) with synthesized 2D mammography results in greater cancer detection rates with fewer recalls. Synthetic mammography uses DBT data to recreate 2D images, requiring no additional radiation. Image quality is key to early detection. Hologic’s, a medical technology company primarily focused on women’s health, direct conversion detector is used in the Selenia Dimensions Hologic, eliminating the need to convert x-rays to light. As a result, the digital images are exceedingly sharp and have a high Detective Quantum Efficiency (DQE), allowing for low-dose tomosynthesis imaging.

Increasing prevalence of breast cancer, technological advancements for the detection and diagnosis of cancer and growing awareness about the benefits of tomosynthesis are some of the factors driving the Digital Breast Tomosynthesis industry forward in the projected period of 2022-2027.

Digital Breast Tomosynthesis Segment Analysis- By Product Type

The Digital Breast Tomosynthesis based on product type can be further segmented into 2D/3D Combination Mammography Systems and Standalone 3D Mammography Systems. 2D/3D Combination Mammography Systems held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 7.9% over the forecast period of 2022-2027. 2D/3D Mammography Systems require less follow-up imaging, detect more cancers than standard mammography alone, and improve breast cancer detection in dense breast tissues. According to a study published in June 2018 in RSNA’s Radiology Journal, 90 percent more breast cancers are detected when doctors combine 2D and 3D mammography. High detection rate, rising awareness among people about 2D/3D combination Mammography system, and increasing prevalence of breast cancer are the key factors driving the market growth. The Screening with Tomosynthesis study, conducted by researchers in Italy in 2016, discovered that the combined procedures detected a greater number of breast cancer cases than 2D mammograms alone. The cancer detection rate for 2D-3D mammography was 8.5 per 1000 screenings, compared to 6.3 per 1000 screens for 2D mammography alone. Technological developments in this segment are predicted to fuel the growth in the forecast period 2022-2027.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=15716

Report Price: $ 4500 (Single User License)

Digital Breast Tomosynthesis Segment Analysis- By End User

The Digital Breast Tomosynthesis based on end-user can be further segmented into Hospitals, Diagnostic Centers, and Others. Hospitals held a dominant market share in the year 2021 owing to increased healthcare infrastructure spending by countries, technological advancements in the hospital industry ad a rising number of breast cancer patients. According to the American Cancer Society, Breast cancer is the second leading cause of cancer death in women. It is about 30% or 1 in 3 of all new female cancers each year which drives the segment growth. The increased demand for Digital Breast Tomosynthesis Systems by doctors is another key factor driving the market growth as it allows them to spot abnormalities that might remain hidden while using conventional mammograms and helps them to detect other signs of breast cancer precisely.

However, the Diagnostic Centres segment is estimated to be the fastest-growing, with a CAGR of 6.2% over the forecast period of 2022-2027 owing to their increasing number globally on account of early wellness testing and diagnostics, awareness on preventive health, and increasing healthcare expenditures. According to the American Cancer Society, the 5-year relative survival rate for breast cancer when identified early and at the localized stage is 99 percent. Monthly breast self-exams, as well as clinical breast exams and mammography, are all part of early detection.

Digital Breast Tomosynthesis Segment Analysis- By Geography

The Digital Breast Tomosynthesis market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 39% in the year 2021 as compared to its other counterparts. It is owing to the trained healthcare professionals, highly developed healthcare infrastructure, higher affordability rate, and increasing incidence of breast cancer disease. Breast cancer is the most frequent cancer among women in the United States. Over the course of their lifetime, one in every eight American women (about 13 percent) will get invasive breast cancer.

However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 9.4% over the forecast period of 2022-2027 owing to increasing government initiatives to promote awareness about breast cancer treatment, investments by companies in developing countries, rising disposable income, and growing population in countries like China and India. For instance, free breast cancer screening is provided to 1 lakh women in Goa as part of the ‘Swasth Mahila, Swasth Goa’ initiative, which was launched by an international cricketing icon in collaboration with the SBI foundation and the state government, ensuring that 50% of the state’s age-eligible female population is screened. BreastScreen Australia is a joint project of the Australian and state and territory governments that aims to minimize breast cancer-related illness and death by early detection. Every two years, women over the age of 40 are given a free mammogram.

Digital Breast Tomosynthesis Market Drivers

Increasing Prevalence of Breast Cancer Is Augmenting the Market Growth

The rising prevalence of breast cancer globally is one of the key drivers of market growth. According to the World Health Organization, 2.3 million women were diagnosed with breast cancer in 2020, with 685 000 fatalities worldwide. Breast cancer had been diagnosed in 7.8 million women in the previous five years as of the end of 2020, making it the most common cancer in the world. Digital Breast Tomosynthesis is a technique that enables the three-dimensional reconstruction of breast tissue, which can then be viewed as consecutive sections across the breast. It increases breast cancer detection while lowering the false-positive or recall rate. Furthermore, it increases the detection of ductal carcinoma in situ, which are little abnormal tissue growths restricted to the milk ducts of the breast (DCIS). If these tumors are removed at an early stage, they rarely cause any harm to the patient, thereby, driving the Digital Breast Tomosynthesis Industry.

Increased awareness about breast cancer and the benefits of tomosynthesis has aided market growth.

The rise in public awareness regarding the advantages of Digital Breast Tomosynthesis, as well as the increase in healthcare expenditure by consumers, are propelling the market growth for Digital Breast Tomosynthesis forward. Many organizations are working towards spreading awareness about breast cancer drugs globally. For instance, in March 2020, World Health Organisation (WHO) hosted an advocacy event “Hearing the call of women with breast cancer” and presented their new initiative named Global Breast Cancer Initiative with the objective of reducing global breast cancer mortality by 2.5% per year until 2040. The Breast Cancer Foundation is always at the forefront for spreading awareness about breast cancer and the latest technological advancements in its treatments, empowerment, and support programs in Malaysia driving the market growth.

Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=15716

Digital Breast Tomosynthesis Market Challenges

High Cost and Excessive Exposure to Radiations Is Limiting The Market Development.

The high operation and installation cost of 2D/3D combination mammography systems is predicted to hinder the Digital Breast Tomosynthesis industry growth during the forecast period. 2D mammography systems cost roughly 30% less as compared to 2D/3D combination mammography systems. Excessive exposure to radiation always carries a small risk of cancer. Digital Breast tomosynthesis uses a slightly higher dose of radiation than 2D mammography. Sometimes 2D/3D combination mammography systems may show an abnormality that after other tests turn out to be benign or consistent with normal tissue. This is known as a false-positive result and it can cause anxiety if the patient decides to go for additional imaging and testing, for instance, a biopsy to further assess the area which costs time and money and even physical discomfort, thereby, limiting the market growth.

Digital Breast Tomosynthesis Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Digital Breast Tomosynthesis Market. The top 10 Digital Breast Tomosynthesis Market companies are-

Hologic, Inc
GE Healthcare
Fujifilm Holdings Corporation
Dexela Ltd.
Planmed OY
Siemens Healthineers
General Medical Merate SpA (IMS GIOTTO SPA)
Analogic Corporation
Trivitron Healthcare
Metaltronica Spa

Recent Developments

In August 2021, FUJIFILM Medical Systems announced that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now offers ScreenPoint Medical’s new, FDA cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States. Transpara is an artificial intelligence (AI) technology aimed at assisting radiologists in improving reading accuracy, reducing reading time, and streamlining workflow.
In December 2020, Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, received FDA clearance and commercial availability for the Company’s Genius AI™ Detection technology. It’s a new deep learning-based software that can assist radiologists to detect probable tumors in tomosynthesis images of the breast. The software provides crucial parameters during image acquisition to assist radiologists in categorizing and prioritizing cases based on their complexity and predicted read time in order to improve workflow and speed up patient care.

Key Takeaways

Geographically, North America held a dominant market share in the year 2021 owing to the increasing prevalence of breast cancer cases and developed healthcare infrastructure. Additionally, Asia-Pacific is expected to offer lucrative growth opportunities to the marketers owing to rising healthcare expenditure and increasing awareness about Digital Breast Tomosynthesis. The robust growth in the end-use industries such as hospitals and diagnostic centers are some of the factors driving the market growth.
The increasing prevalence of breast cancer globally and technological advancements is predicted to augment the market growth during the forecast period of 2022-2027. Hugh operation and installation cost accompanied with the risk of harmful radiations continues to pose threat to the market growth.
A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Digital Breast Tomosynthesis Market Report.

Relevant Title:

Metastatic Breast Cancer Market

https://www.industryarc.com/Report/16161/metastatic-breast-cancer-market.html

For more Lifescience and Healthcare related reports, please click here

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/